The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.

Cancer Cell, 2018/06/11;33(6):1128-1141.e7.

McBride MJ[1], Pulice JL[2], Beird HC[3], Ingram DR[4], D'Avino AR[2], Shern JF[5], Charville GW[6], Hornick JL[7], Nakayama RT[8], Garcia-Rivera EM[2], Araujo DM[9], Wang WL[4], Tsai JW[4], Yeagley M[9], Wagner AJ[10], Futreal PA[3], Khan J[5], Lazar AJ[11], Kadoch C[12]

Affiliations

PMID: 29861296DOI: 10.1016/j.ccell.2018.05.002

Impact factor: 38.585

Abstract
Synovial sarcoma (SS) is defined by the hallmark SS18-SSX fusion oncoprotein, which renders BAF complexes aberrant in two manners: gain of SSX to the SS18 subunit and concomitant loss of BAF47 subunit assembly. Here we demonstrate that SS18-SSX globally hijacks BAF complexes on chromatin to activate an SS transcriptional signature that we define using primary tumors and cell lines. Specifically, SS18-SSX retargets BAF complexes from enhancers to broad polycomb domains to oppose PRC2-mediated repression and activate bivalent genes. Upon suppression of SS18-SSX, reassembly of BAF47 restores enhancer activation, but is not required for proliferative arrest. These results establish a global hijacking mechanism for SS18-SSX on chromatin, and define the distinct contributions of two concurrent BAF complex perturbations.

Keywords: ATP-dependent chromatin remodeling; SWI/SNF (BAF) complexes; bivalency; chromatin; enhancers; fusion oncoprotein; pediatric cancer; polycomb; synovial sarcoma

MeSH terms
More resources
EndNote: Download